{"url_path":"/sec/okyo/10-k/2026/item-16g","section_key":"item-16g","section_title":"Item 16G CORPORATE GOVERNANCE**","topic":"sec","document":{"doc_type":"20-F","doc_date":"2026-07-20","source_url":"https://www.sec.gov/Archives/edgar/data/1849296/0001493152-26-033847-index.html","accession_number":"0001493152-26-033847","cik":"0001849296","ticker":"OKYO","issuer_name":"OKYO Pharma Ltd","edgar_url":"https://www.sec.gov/Archives/edgar/data/1849296/0001493152-26-033847-index.html","primary_entity_key":"0001849296","primary_entity_name":"OKYO Pharma Ltd"},"word_count":354,"has_tables":true,"body_markdown":"**ITEM\n16G: CORPORATE GOVERNANCE**\n\n \n\nThe\nSarbanes-Oxley Act of 2002, as well as related rules subsequently implemented by the SEC, requires foreign private issuers, including\nour company, to comply with various corporate governance practices. In addition, NASDAQ rules provide that foreign private issuers may\nfollow home country practices in lieu of the NASDAQ corporate governance standards, subject to certain exceptions and except to the extent\nthat such exemptions would be contrary to U.S. federal securities laws. The home country practices followed by our company in lieu of\nNASDAQ rules are described below:\n\n \n\n \n●\nWe do not follow NASDAQ’s\nquorum requirements applicable to meetings of shareholders. Such quorum requirements are not required under Guernsey law. In accordance\nwith generally accepted business practice, our articles of association provide alternative quorum requirements that are generally\napplicable to meetings of shareholders.\n\n \n \n \n\n \n●\nWe do not follow NASDAQ’s\nrequirements that non-management directors meet on a regular basis without management present. Our board of directors may choose\nto meet in executive session at their discretion.\n\n \n \n \n\n \n●\nWe do not follow NASDAQ’s\nrequirements to seek shareholder approval for the implementation of certain equity compensation plans, the issuances of ordinary\nshares under such plans, or in connection with certain private placements of equity securities. In accordance with Guernsey law,\nwe are not required to seek shareholder approval to allot ordinary shares in connection with applicable employee equity compensation\nplans. We will follow Guernsey law with respect to any requirement to obtain shareholder approval prior to any private placements\nof equity securities.\n\n \n\nWe\nintend to take all actions necessary for us to maintain compliance as a foreign private issuer under the applicable corporate governance\nrequirements of the Sarbanes-Oxley Act of 2002, the rules adopted by the SEC and NASDAQ’s listing standards.\n\n \n\nBecause\nwe are a foreign private issuer, our directors and senior management are not subject to short-swing profit and insider trading reporting\nobligations under Section 16 of the U.S. Securities Exchange Act of 1934, as amended, or Exchange Act. They are, however, subject to\nthe obligations to report changes in share ownership under Section 13 of the Exchange Act and related SEC rules."}